REGENICIN, INC. (OTCMKTS:RGIN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

Effective August 7, 2017, Dr. Craig Eagle resigned from of our board of directors. There was no known disagreement with Dr. Eagle on any matter relating to the Company’s operations, policies or practices.

About REGENICIN, INC. (OTCMKTS:RGIN)

Regenicin, Inc., formerly Windstar, Inc., focuses on developing and commercializing a lifesaving technology by the introduction of tissue-engineered skin substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a range of plastic surgery procedures The Company is engaged in the process of validating its collagen scaffold to demonstrate safety. The Company’s cultured skin substitute product is a multi-layered tissue-engineered skin prepared by utilizing autologous (patient’s own) skin cells. It is a graftable collagen-based cultured epithelium implant that produces a skin substitute containing both epidermal and dermal components with a collagen base. The Company’s product, TempaDerm, uses cells obtained from human donors to develop banks of cryo-preserved (frozen) cells and cultured skin substitute to provide a continuous supply of non-allogenic skin substitutes to treat smaller wound areas on patients, such as ulcers.